Filing Flows

Filing Flows › Companies › Bioadaptives › Cash flow

Bioadaptives cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$44K in Q2 2026 · −$436K over twelve months

Operating cash flow−$44K
Free cash flow−$44K
Cash / net income-0.3×

Analysis

In Q2 2026, Bioadaptives generated −$44K of operating cash flow. That is $67K more than in Q2 2025 (−$111K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$436K; the largest uses were operating cash flow ($436K); besides operations, cash came from other financing ($255K); the cash balance fell by $181K.

Operating cash flow was −$44K against net income of $150K — -0.3× profit, less cash than reported earnings, worth checking against working capital. The largest differences: payables +$46K, inventory +$7K, prepaid and other assets +$2K.

Free cash flow

Bioadaptives: free cash flow by quarterBioadaptives: free cash flow by quarter−$56KQ3 2024−$101KQ4 2024−$98KQ1 2025−$111KQ2 2025−$151KQ3 2025−$156KQ4 2025−$85KQ1 2026−$44KQ2 2026
Operating cash flow less capital spending.
Bioadaptives: operating cash flow against capital spendingBioadaptives: operating cash flow against capital spendingOperating cash flowCapital spending−$56K$0Q3 2024−$101K$0Q4 2024−$98K$0Q1 2025−$111K$0Q2 2025−$151K$0Q3 2025−$156K$0Q4 2025−$85K$0Q1 2026−$44K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$44K, Capital spending $0.

Capital allocation, year by year

Bioadaptives: where the cash came from (up) and went (down), by fiscal yearBioadaptives: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$159KFY2021: Net borrowing $217KFY2021: Shares issued $565K$782KFY2021FY2022: Operating cash flow −$227KFY2022: Net borrowing $144K$144KFY2022FY2023: Operating cash flow −$224KFY2023: Net borrowing $80KFY2023: Shares issued $178K$258KFY2023FY2024: Operating cash flow −$250KFY2024: Net borrowing −$2KFY2024: Shares issued $294K$294KFY2024FY2025: Operating cash flow −$516KFY2025: Net borrowing $255KFY2025: Shares issued $300KFY2025: Capital spending −$18K$555KFY2025
Over these 5 years operating cash flow totalled −$1.4M; the largest uses were operating cash flow ($1.4M) and capital spending ($18K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$29K
Debtnone
Net cash$29K
Cash runway1 month

Bioadaptives is burning cash: its operations consume cash, a free cash flow of −$436K a year at the current rate against $29K of cash and investments: a runway of about 1 month before any new financing.

Where the cash came from and went

Bioadaptives: sources (+) and uses (−) of cash, Q2 2026Bioadaptives: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$44KCash drawn (+) / kept (−)$44K
Bioadaptives: sources (+) and uses (−) of cash, TTM to Q2 2026Bioadaptives: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$436KOther financing$255KCash drawn (+) / kept (−)$181K

From profit to cash

Bioadaptives: net income to operating cash flow, Q2 2026Bioadaptives: net income to operating cash flow, Q2 2026Net income$150KDepreciation & amortization$2KInventory$7KPayables$46KPrepaid and other assets$2KOperating cash flow−$44K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$44K——$44K−$44K
Q1 2026−$85K——$85K−$85K
Q4 2025−$156K——−$99K−$156K
Q3 2025−$151K——$151K−$151K
Q2 2025−$111K——−$171K−$111K
Q1 2025−$98K——$98K−$98K
Q4 2024−$101K−$1K$194K−$94K−$101K
Q3 2024−$56K—$100K−$44K−$56K

Bioadaptives: income statement and cash flow

Bioadaptives, Q2 2026: revenue $5K (+55% year over year). The chart follows the revenue to costs, profit and cash.

Bioadaptives: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.